Molecular biology of calcific aortic valve disease: towards new pharmacological therapies
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Calcific aortic valve disease (CAVD) is a chronic process leading to fibrosis and mineralization of the aortic valve. Investigations in the last several years have emphasized that key underlying molecular processes are involved in the pathogenesis of CAVD. In this regard, the processing of lipids and their retention has been underlined as an important mechanism that triggers inflammation. In turn, inflammation promotes/enhances the mineralization of valve interstitial cells, the main cellular component of the aortic valve. On the other hand, transformation of valve interstitial cells into myofibroblasts and osteoblast-like cells is determined by several signaling pathways having reciprocal cross-talks. In addition, the mineralization of the aortic valve has been shown to rely on ectonucleotidase and purinergic signaling. In this review, the authors have highlighted key molecular underpinnings of CAVD that may have significant relevance for the development of novel pharmaceutical therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029 · cited 2×
“In this regard, the prevalence of CAVD is 15–25% in subjects over 65 years [2].”
BackgroundMutations in NOTCH1 cause aortic valve disease
Garg, V., Muth, A. N., Ransom, J. F., Schluterman, M. K., Barnes, R., King, I. N., Grossfeld, P. D., & Srivastava, D. (2005) · Nature · doi:10.1038/nature03940 · Cited by 1,509
Genetic Associations with Valvular Calcification and Aortic Stenosis
Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109034 · Cited by 1,008
Rajamannan, N. M., Evans, F. J., Aikawa, E., Grande-Allen, K. J., Demer, L. L., Heistad, D. D., Simmons, C. A., Masters, K. S., Mathieu, P., O'Brien, K. D., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.006767 · Cited by 842 · cited 2×
“Progressive and pathological mineralization of leaflets are the root cause of CAVD [1].”
BackgroundSelf-citationMendelian randomization of blood lipids for coronary heart disease
Holmes, M. V., Asselbergs, F. W., Palmer, T. M., Drenos, F., Lanktree, M. B., Nelson, C. P., Dale, C. E., Padmanabhan, S., Finan, C., Swerdlow, D. I., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/eht571 · Cited by 748 · cited 1×
“However, Mendelian randomized studies suggested that HDLs may not be causally related to atherosclerosis [34].”
BackgroundElevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595 · cited 1×
“showed that in a Mandelian randomization study design including 77,680 subjects followed over 20 years, carriers of the genetic LPA variants rs10455872 and rs3798220 had elevated blood plasma levels of Lp(a), which was independently associated with the risk of developing CAVD [26].”
BackgroundDarapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
The STABILITY Investigators (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315878 · Cited by 579 · cited 1×
“In a recent randomized trial in patients with coronary artery disease, darapladib did not modify the cardiovascular outcomes [30].”
BackgroundPresence of Oxidized Low Density Lipoprotein in Nonrheumatic Stenotic Aortic Valves
Olsson, M., Thyberg, J., & Nilsson, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.5.1218 · Cited by 417
Arsenault, B. J., Boekholdt, S. M., Dubé, M.-P., Rhéaume, É., Wareham, N. J., Khaw, K.-T., Sandhu, M. S., & Tardif, J.-C. (2014) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.113.000400 · Cited by 315
Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease
Li, H., & Förstermann, U. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.01.006 · Cited by 285
Inflammation Is Associated with the Remodeling of Calcific Aortic Valve Disease
Coté, N., Mahmut, A., Bosse, Y., Couture, C., Pagé, S., Trahan, S., Boulanger, M.-C., Fournier, D., Pibarot, P., & Mathieu, P. (2013) · Inflammation · doi:10.1007/s10753-012-9579-6 · Cited by 218 · cited 1×
“showed that in 285 patients, the presence of dense inflammatory infiltrates in the aortic valve of patients operated for CAVD was associated with a higher remodeling score of the aortic valve and with a greater density of neovascularization [50].”
BackgroundSelf-citationMohty, D., Pibarot, P., Després, J.-P., Côté, C., Arsenault, B., Cartier, A., Cosnay, P., Couture, C., & Mathieu, P. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.154989 · Cited by 181 · cited 1×
“previously documented that a high proportion of circulating small, dense LDL was associated with aortic valve accumulation of ox-LDL, inflammation and a faster hemodynamic progression rate of stenosis [14].”
BackgroundSelf-citationEl Husseini, D., Boulanger, M.-C., Mahmut, A., Bouchareb, R., Laflamme, M.-H., Fournier, D., Pibarot, P., Bossé, Y., & Mathieu, P. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.02.014 · Cited by 150 · cited 2×
“documented that in stenotic aortic valves, there is an activation of the nuclear factor-kB (NF-kB) pathway as exemplified by high level of phosphorylated IkB in mineralized tissues [60].”
BackgroundSelf-citationBossé, Y., Miqdad, A., Fournier, D., Pépin, A., Pibarot, P., & Mathieu, P. (2009) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.108.820795 · Cited by 148 · cited 1×
“In explanted human aortic valves, the expression of osteogenic transcription factors and bone morphogenetic proteins (BMPs) is increased [4].”
BackgroundSelf-citationImpact of Metabolic Syndrome on Progression of Aortic Stenosis
Capoulade, R., Clavel, M.-A., Dumesnil, J. G., Chan, K. L., Teo, K. K., Tam, J. W., Côté, N., Mathieu, P., Després, J.-P., & Pibarot, P. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.052 · Cited by 127 · cited 1×
“A recent post hoc analysis of the ASTRONOMER study, a randomized trial comparing rosuvastatin with a placebo in aortic stenosis, has underscored that in patients with the metabolic syndrome statins were associated with a higher resistance to insulin and a faster progression rate of stenosis [15].”
MethodSelf-citationMerki, E., Graham, M., Taleb, A., Leibundgut, G., Yang, X., Miller, E. R., Fu, W., Mullick, A. E., Lee, R., Willeit, P., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.052 · Cited by 124 · cited 1×
“Antisense oligonucleotides have been developed for Lp(a) and have been shown in an animal model to reduce substantially the level of Lp (a) [31].”
BackgroundCôté, C., Pibarot, P., Després, J.-P., Mohty, D., Cartier, A., Arsenault, B. J., Couture, C., & Mathieu, P. (2008) · Heart · doi:10.1136/hrt.2007.125740 · Cited by 121
Self-citationImpact of hypertension and renin–angiotensin system inhibitors in aortic stenosis
Capoulade, R., Clavel, M., Mathieu, P., Côté, N., Dumesnil, J. G., Arsenault, M., Bédard, É., & Pibarot, P. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12169 · Cited by 97 · cited 1×
“showed that in an observational prospective study, angiotensin type 1 receptor blockers (ARBs) but not angiotensin-converting enzyme (ACE) inhibitors were associated with a decrease progression rate of aortic stenosis [67].”
BackgroundSelf-citationATP acts as a survival signal and prevents the mineralization of aortic valve
Côté, N., El Husseini, D., Pépin, A., Guauque-Olarte, S., Ducharme, V., Bouchard-Cannon, P., Audet, A., Fournier, D., Gaudreault, N., Derbali, H., et al. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.02.003 · Cited by 95 · cited 2×
“Recently, singlenucleotide polymorphisms for ectonucleotide pyrophosphatase/ phosphodiesterase 1 (ENPP1) were significantly associated with CAVD [97].”
BackgroundSelf-citationSong, R., Zeng, Q., Ao, L., Yu, J. A., Cleveland, J. C., Zhao, K.-S., Fullerton, D. A., & Meng, X. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300116 · Cited by 86 · cited 1×
“A recent work has also underlined that stimulation of TLR2 by biglycan promotes and exacerbates the mineralization of VICs [19].”
BackgroundDerbali, H., Bossé, Y., Côté, N., Pibarot, P., Audet, A., Pépin, A., Arsenault, B., Couture, C., Després, J.-P., & Mathieu, P. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090541 · Cited by 71
Self-citationFujisaka, T., Hoshiga, M., Hotchi, J., Takeda, Y., Jin, D., Takai, S., Hanafusa, T., & Ishizaka, N. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.10.055 · Cited by 55 · cited 1×
“In mice, the administration of angiotensin II, at a dosage that did not affect blood pressure, resulted in thickening of the aortic valve [69].”
BackgroundPioglitazone attenuates valvular calcification induced by hypercholesterolemia
Chu, Y., Lund, D. D., Weiss, R. M., Brooks, R. M., Doshi, H., Hajj, G. P., Sigmund, C. D., & Heistad, D. D. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300794 · Cited by 49
Osman, N., Grande-Allen, K. J., Ballinger, M. L., Getachew, R., Marasco, S., O'Brien, K. D., & Little, P. J. (2013) · Cardiovascular Pathology · doi:10.1016/j.carpath.2012.07.002 · Cited by 32
Lipoprotein lipase in aortic valve stenosis is associated with lipid retention and remodelling
Mahmut, A., Boulanger, M., Fournier, D., Couture, C., Trahan, S., Pagé, S., Arsenault, B., Després, J., Pibarot, P., & Mathieu, P. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12081 · Cited by 31 · cited 2×
“Lipoprotein lipase (LPL) is also expressed in stenotic aortic valves where it colocalized with ox-LDL and decorin [21].”
BackgroundSelf-citation
Cited by
WNT Signaling in Cardiac and Vascular Disease
Foulquier, S., Daskalopoulos, E. P., Lluri, G., Hermans, K. C. M., Deb, A., & Blankesteijn, W. M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.013896 · Cited by 347
Innate and Adaptive Immunity in Calcific Aortic Valve Disease
Mathieu, P., Bouchareb, R., & Boulanger, M.-C. (2015) · Journal of Immunology Research · doi:10.1155/2015/851945 · Cited by 121
Self-citationGuauque-Olarte, S., Droit, A., Tremblay-Marchand, J., Gaudreault, N., Kalavrouziotis, D., Dagenais, F., Seidman, J. G., Body, S. C., Pibarot, P., Mathieu, P., et al. (2016) · Physiological Genomics · doi:10.1152/physiolgenomics.00041.2016 · Cited by 82
“No effective medical treatment can prevent or slow the progression of AS (21).”
BackgroundSelf-citationLi, Z., Gaudreault, N., Arsenault, B. J., Mathieu, P., Bossé, Y., & Thériault, S. (2020) · Communications Biology · doi:10.1038/s42003-020-01210-x · Cited by 23
Self-citation
Metadata
- Authors
- Mathieu, P., Boulanger, M.-C., & Bouchareb, R.
- Venue
- Expert Review of Cardiovascular Therapy
- Publisher
- Informa UK Limited
- Published
- 2014-05-24
- Volume
- 12
- Issue
- 7
- Pages
- 851-862
- ISSN
- 1477-9072 (ISSN-L)
- 1744-8344
- OpenAlex
- W2124158335
- Cited by
- 52
- References
- 25
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.